intron A

BIOLOGICAL2 trials

Sponsors

University Hospital, Bordeaux, Merck Sharp & Dohme LLC

Conditions

MelanomaNeoplasm Metastasis

Phase 2

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

TerminatedNCT03552549

Merck Sharp & Dohme LLCMelanoma

Start: 1998-08-05End: 2001-02-19Updated: 2019-07-24

Phase 3

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)

CompletedNCT00221702

University Hospital, BordeauxMelanoma, Neoplasm Metastasis

Start: 2003-06-30End: 2010-10-31Updated: 2010-10-13

Related Papers

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.

2012-09-1026 citations